Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Terconazole | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | Terconazole | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Terconazole | hsa00190 | Oxidative phosphorylation | 2.11E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Terconazole | hsa00220 | Arginine biosynthesis | 1.26E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Terconazole | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | | Terconazole | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Terconazole | hsa00500 | Starch and sucrose metabolism | 6.40E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Terconazole | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | Terconazole | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | | Terconazole | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Terconazole | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Terconazole | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.32E-02 | 2 | P40925, P15104 | MDH1, GLUL | More | | Terconazole | hsa00730 | Thiamine metabolism | 5.86E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Terconazole | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Terconazole | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Terconazole | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Terconazole | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Terconazole | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Terconazole | hsa00983 | Drug metabolism - other enzymes | 4.00E-04 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Terconazole | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Terconazole | hsa01230 | Biosynthesis of amino acids | 2.16E-03 | 5 | P51854, Q99707, P50213, P15104, P37837 | TKTL1, MTR, IDH3A, GLUL, TALDO1 | More | | Terconazole | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Terconazole | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Terconazole | hsa03013 | RNA transport | 8.18E-05 | 9 | P38919, Q15287, Q9UBU9, P37198, P35658, P63279, P55884, O15371, P20042 | EIF4A3, RNPS1, NXF1, NUP62, NUP214, UBE2I, EIF3B, EIF3D, EIF2S2 | More | | Terconazole | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Terconazole | hsa03040 | Spliceosome | 4.49E-05 | 13 | Q14562, O43143, O60508, P08579, Q15427, P38159, P61978, Q07955, Q01130, Q13243, P11142, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, SF3B4, RBMX, HNRPK, SFRS1, SFRS2, SFRS5, HSPA8, PPIH, ASCC3L1 | More | | Terconazole | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Terconazole | hsa03060 | Protein export | 1.43E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Terconazole | hsa04012 | ErbB signaling pathway | 1.66E-03 | 7 | P21860, P16333, Q13557, P19174, O14944, P42338, P01106 | ERBB3, NCK1, CAMK2D, PLCG1, EREG, PIK3CB, MYC | More | | Terconazole | hsa04014 | Ras signaling pathway | 2.92E-04 | 10 | P42338, P20827, Q9NRA1, P49767, Q13009, P0DP23, P62873, P63218, P50151, P19174 | PIK3CB, EFNA1, PDGFC, VEGFC, TIAM1, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Terconazole | hsa04015 | Rap1 signaling pathway | 4.83E-04 | 12 | P20827, Q9NRA1, P49767, P11215, P25116, Q8TEU7, Q13009, P42338, P0DP23, P08514, P17252, P19174 | EFNA1, PDGFC, VEGFC, ITGAM, F2R, RAPGEF6, TIAM1, PIK3CB, CALM1, ITGA2B, PRKCA, PLCG1 | More | | Terconazole | hsa04020 | Calcium signaling pathway | 1.09E-04 | 12 | P27987, Q96DU7, P21796, P45880, Q13557, P21860, P19174, P0DP23, P51828, P23634, Q9NRA1, P49767 | ITPKB, ITPKC, VDAC1, VDAC2, CAMK2D, ERBB3, PLCG1, CALM1, ADCY7, ATP2B4, PDGFC, VEGFC | More | | Terconazole | hsa04022 | cGMP-PKG signaling pathway | 4.72E-02 | 4 | Q99941, P23634, P51828, P45880 | CREBL1, ATP2B4, ADCY7, VDAC2 | More | | Terconazole | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Terconazole | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | | Terconazole | hsa04062 | Chemokine signaling pathway | 9.17E-06 | 16 | P25024, P09341, P47992, Q9UBD3, P07948, P42338, P19174, P62873, P63218, P50151, P43250, Q08881, Q13009, P14598, P42224, P25963 | CXCR1, CXCL1, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, ITK, TIAM1, NCF1, STAT1, NFKBIA | More | | Terconazole | hsa04064 | NF-kappa B signaling pathway | 7.03E-04 | 11 | O00463, P14778, Q04759, Q13077, Q16548, P07948, P06239, Q8WV28, P24522, P09341, Q06643 | TRAF5, IL1R1, PRKCQ, TRAF1, BCL2A1, LYN, LCK, BLNK, GADD45A, CXCL1, LTB | More | | Terconazole | hsa04070 | Phosphatidylinositol signaling system | 1.12E-02 | 5 | P19174, P0DP23, P42338, P23743, P27987 | PLCG1, CALM1, PIK3CB, DGKA, ITPKB | More | | Terconazole | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | | Terconazole | hsa04072 | Phospholipase D signaling pathway | 4.67E-02 | 5 | P42338, P19174, Q14344, P23743, Q9NRA1 | PIK3CB, PLCG1, GNA13, DGKA, PDGFC | More | | Terconazole | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | | Terconazole | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Terconazole | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Terconazole | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | | Terconazole | hsa04142 | Lysosome | 3.80E-03 | 4 | Q99437, P08311, P25774, Q9UPM8 | ATP6V0B, CTSG, CTSS, AP4E1 | More | | Terconazole | hsa04145 | Phagosome | 3.11E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Terconazole | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Terconazole | hsa04151 | PI3K-Akt signaling pathway | 5.62E-03 | 12 | P42338, P01106, P20827, Q9NRA1, P49767, P08238, P62873, P63218, P50151, O15335, P14784, P01568 | PIK3CB, MYC, EFNA1, PDGFC, VEGFC, HSP90AB1, GNB1, GNG5, GNG10, CHAD, IL2RB, IFNA21 | More | | Terconazole | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Terconazole | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | Terconazole | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Terconazole | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.98E-02 | 4 | P51828, Q99941, Q13557, P23634 | ADCY7, CREBL1, CAMK2D, ATP2B4 | More | | Terconazole | hsa04330 | Notch signaling pathway | 2.46E-03 | 3 | Q92542, P49768, P46531 | NCSTN, PSEN1, NOTCH1 | More | | Terconazole | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Terconazole | hsa04360 | Axon guidance | 2.87E-02 | 5 | P16333, P20827, O95631, P42338, P19174 | NCK1, EFNA1, NTN1, PIK3CB, PLCG1 | More | | Terconazole | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Terconazole | hsa04371 | Apelin signaling pathway | 2.41E-03 | 7 | P62873, P63218, P50151, Q13370, Q14814, Q14344, P0DP23 | GNB1, GNG5, GNG10, PDE3B, MEF2D, GNA13, CALM1 | More | | Terconazole | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Terconazole | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | | Terconazole | hsa04612 | Antigen processing and presentation | 1.75E-02 | 6 | P13765, P01730, P26715, P26717, Q13241, P01732 | HLA-DOB, CD4, KLRC1, KLRC2, KLRD1, CD8A | More | | Terconazole | hsa04613 | Neutrophil extracellular trap formation | 9.10E-07 | 19 | P42338, P19174, P11215, P05164, Q13547, P04908, Q93077, P58876, P62807, Q93079, Q16778, O60814, P68431, P21796, P14598, P20160, P08311, O43315, Q16539 | PIK3CB, PLCG1, ITGAM, MPO, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, H2BC9, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, VDAC1, NCF1, AZU1, CTSG, AQP9, MAPK14 | More | | Terconazole | hsa04620 | Toll-like receptor signaling pathway | 4.00E-02 | 4 | P01568, P42224, P25963, P42338 | IFNA21, STAT1, NFKBIA, PIK3CB | More | | Terconazole | hsa04623 | Cytosolic DNA-sensing pathway | 3.67E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Terconazole | hsa04625 | C-type lectin receptor signaling pathway | 2.17E-02 | 5 | Q9ULY5, P42224, P25963, P42338, P0DP23 | CLEC4E, STAT1, NFKBIA, PIK3CB, CALM1 | More | | Terconazole | hsa04640 | Hematopoietic cell lineage | 3.30E-05 | 11 | P13612, P14778, P27930, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765 | ITGA4, IL1R1, IL1R2, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB | More | | Terconazole | hsa04650 | Natural killer cell mediated cytotoxicity | 1.62E-04 | 11 | P16298, P50591, P06239, O60880, P20963, Q02750, Q13241, P26718, O14931, P26717, P26715 | PPP3CB, TNFSF10, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | | Terconazole | hsa04657 | IL-17 signaling pathway | 5.03E-03 | 6 | O00463, Q16539, P49841, P09341, P14780, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, TNF | More | | Terconazole | hsa04658 | Th1 and Th2 cell differentiation | 2.74E-08 | 14 | P25963, Q04759, P07766, P20963, P09693, P19174, P01730, P06239, P42224, P23771, Q9UL17, P14784, P13765, Q13761 | NFKBIA, PRKCQ, CD3E, CD247, CD3G, PLCG1, CD4, LCK, STAT1, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Terconazole | hsa04659 | Th17 cell differentiation | 8.09E-08 | 17 | P25963, Q04759, P19174, P01730, P06239, P42224, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, HSP90AB1, CD3E, CD3G, CD247 | More | | Terconazole | hsa04660 | T cell receptor signaling pathway | 8.91E-04 | 9 | Q04759, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239 | PRKCQ, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK | More | | Terconazole | hsa04662 | B cell receptor signaling pathway | 1.12E-02 | 5 | P25963, P42338, P07948, P21854, Q8N149 | NFKBIA, PIK3CB, LYN, CD72, LILRA2 | More | | Terconazole | hsa04664 | Fc epsilon RI signaling pathway | 1.34E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Terconazole | hsa04666 | Fc gamma R-mediated phagocytosis | 2.92E-02 | 4 | P07948, P42338, P19174, P14598 | LYN, PIK3CB, PLCG1, NCF1 | More | | Terconazole | hsa04668 | TNF signaling pathway | 4.74E-02 | 3 | Q99941, P01584, O95429 | CREBL1, IL1B, BAG4 | More | | Terconazole | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | | Terconazole | hsa04713 | Circadian entrainment | 4.00E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | | Terconazole | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Terconazole | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Terconazole | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Terconazole | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Terconazole | hsa04724 | Glutamatergic synapse | 2.92E-02 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Terconazole | hsa04725 | Cholinergic synapse | 2.92E-02 | 4 | P62873, P63218, P50151, P42338 | GNB1, GNG5, GNG10, PIK3CB | More | | Terconazole | hsa04727 | GABAergic synapse | 8.14E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Terconazole | hsa04744 | Phototransduction | 1.32E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Terconazole | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.11E-03 | 7 | P01584, P51828, Q13557, P19174, P42338, P24723, P0DP23 | IL1B, ADCY7, CAMK2D, PLCG1, PIK3CB, PRKCH, CALM1 | More | | Terconazole | hsa04810 | Regulation of actin cytoskeleton | 2.61E-02 | 6 | P12814, Q13009, P42338, P11215, Q14344, Q9NRA1 | ACTN1, TIAM1, PIK3CB, ITGAM, GNA13, PDGFC | More | | Terconazole | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Terconazole | hsa04911 | Insulin secretion | 1.48E-02 | 3 | P51828, Q99941, Q13557 | ADCY7, CREBL1, CAMK2D | More | | Terconazole | hsa04914 | Progesterone-mediated oocyte maturation | 4.29E-03 | 7 | Q17RY0, P42338, Q13370, P30304, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, CDC25A, HSP90AB1, RPS6KA3, MAP2K1 | More | | Terconazole | hsa04915 | Estrogen signaling pathway | 4.72E-02 | 4 | Q99941, P51828, P07900, P11142 | CREBL1, ADCY7, HSP90AA1, HSPA8 | More | | Terconazole | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | Terconazole | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Terconazole | hsa04925 | Aldosterone synthesis and secretion | 5.19E-03 | 4 | Q99941, P51828, Q13557, P23634 | CREBL1, ADCY7, CAMK2D, ATP2B4 | More | | Terconazole | hsa04926 | Relaxin signaling pathway | 8.74E-03 | 6 | P25963, P42338, P62873, P63218, P50151, P49767 | NFKBIA, PIK3CB, GNB1, GNG5, GNG10, VEGFC | More | | Terconazole | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Terconazole | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Terconazole | hsa04934 | Cushing syndrome | 3.48E-03 | 4 | Q99941, P51828, O15169, Q13557 | CREBL1, ADCY7, AXIN1, CAMK2D | More | | Terconazole | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Terconazole | hsa04971 | Gastric acid secretion | 1.48E-02 | 3 | P51828, P15311, Q13557 | ADCY7, VIL2, CAMK2D | More | | Terconazole | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Terconazole | hsa05010 | Alzheimer disease | 2.07E-02 | 7 | Q92542, P05496, P12074, O75460, P01584, O15169, P45880 | NCSTN, ATP5G1, COX6A1, ERN1, IL1B, AXIN1, VDAC2 | More | | Terconazole | hsa05012 | Parkinson disease | 4.01E-02 | 6 | P21796, P60604, P19174, P0DP23, Q71U36, Q13509 | VDAC1, UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3 | More | | Terconazole | hsa05020 | Prion disease | 1.37E-03 | 11 | P01584, P46531, P11142, Q16718, O14521, P05496, P12074, P45880, P49841, Q99941, Q16539 | IL1B, NOTCH1, HSPA8, NDUFA5, SDHD, ATP5G1, COX6A1, VDAC2, GSK3B, CREBL1, MAPK14 | More | | Terconazole | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Terconazole | hsa05032 | Morphine addiction | 7.60E-03 | 5 | P62873, P63218, P50151, Q13370, P43250 | GNB1, GNG5, GNG10, PDE3B, GRK6 | More | | Terconazole | hsa05034 | Alcoholism | 1.63E-06 | 12 | Q13547, P0DP23, P62873, P63218, P50151, Q93077, P58876, P62807, Q93079, Q16778, O60814, P68431 | HDAC1, CALM1, GNB1, GNG5, GNG10, HIST1H2AC, H2BC5, HIST1H2BC, H2BC9, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Terconazole | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | Terconazole | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | Terconazole | hsa05132 | Salmonella infection | 2.36E-02 | 8 | P25963, P08238, P01106, P42338, O75369, Q71U36, Q13509, P49754 | NFKBIA, HSP90AB1, MYC, PIK3CB, FLNB, TUBA1A, TUBB3, VPS41 | More | | Terconazole | hsa05140 | Leishmaniasis | 4.21E-04 | 9 | O75015, P14598, P13765, O60603, P25963, P29350, P49006, Q16539, Q15080 | FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, PTPN6, MARCKSL1, MAPK14, NCF4 | More | | Terconazole | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Terconazole | hsa05146 | Amoebiasis | 1.32E-03 | 7 | P09341, P14778, P27930, O60603, P05089, P12814, P08311 | CXCL1, IL1R1, IL1R2, TLR2, ARG1, ACTN1, CTSG | More | | Terconazole | hsa05152 | Tuberculosis | 4.16E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Terconazole | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Terconazole | hsa05162 | Measles | 1.84E-02 | 7 | P01568, P25963, P42224, P14784, P07766, P42338, P11142 | IFNA21, NFKBIA, STAT1, IL2RB, CD3E, PIK3CB, HSPA8 | More | | Terconazole | hsa05163 | Human cytomegalovirus infection | 7.99E-05 | 17 | P42338, P25963, P62873, P63218, P50151, Q14643, P0DP23, Q14344, P49841, P01106, P14778, P25025, Q16539, P04637, O00463, P30101, P01568 | PIK3CB, NFKBIA, GNB1, GNG5, GNG10, ITPR1, CALM1, GNA13, GSK3B, MYC, IL1R1, CXCR2, MAPK14, TP53, TRAF5, PDIA3, IFNA21 | More | | Terconazole | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.21E-06 | 15 | P01568, P42224, P25963, P42338, P62873, P62879, P63218, P50151, P19174, P16298, Q02750, P07948, P01106, P0DP23, P0CG47 | IFNA21, STAT1, NFKBIA, PIK3CB, GNB1, GNB2, GNG5, GNG10, PLCG1, PPP3CB, MAP2K1, LYN, MYC, CALM1, UBB | More | | Terconazole | hsa05168 | Herpes simplex virus 1 infection | 4.57E-02 | 10 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, P42338, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, PIK3CB, ZNF211, ZNF189 | More | | Terconazole | hsa05169 | Epstein-Barr virus infection | 1.94E-05 | 16 | P13765, P01106, Q13547, O00463, P25963, P42338, P07948, P30101, Q13761, P24522, O75293, P42224, P01568, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, NFKBIA, PIK3CB, LYN, PDIA3, RUNX3, GADD45A, GADD45B, STAT1, IFNA21, CD3E, CD3G, CD247 | More | | Terconazole | hsa05170 | Human immunodeficiency virus 1 infection | 5.72E-05 | 15 | P42338, Q02750, P62873, P62879, P63218, P50151, P16298, P0DP23, Q05397, P30101, P01568, P25963, P19174, P07766, P20333 | PIK3CB, MAP2K1, GNB1, GNB2, GNG5, GNG10, PPP3CB, CALM1, PTK2, PDIA3, IFNA21, NFKBIA, PLCG1, CD3E, TNFRSF1B | More | | Terconazole | hsa05200 | Pathways in cancer | 1.82E-03 | 17 | P42338, P08238, P42224, P25963, P19174, P01106, P43246, Q13547, P49767, P62873, P63218, P50151, Q14344, O75293, P0DP23, P01568, P14784 | PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, MYC, MSH2, HDAC1, VEGFC, GNB1, GNG5, GNG10, GNA13, GADD45B, CALM1, IFNA21, IL2RB | More | | Terconazole | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | Terconazole | hsa05203 | Viral carcinogenesis | 2.90E-05 | 13 | P42338, P06746, P07948, P29083, Q13547, Q15283, P12814, P25963, P58876, P62807, Q93079, Q16778, O60814 | PIK3CB, POLB, LYN, GTF2E1, HDAC1, RASA2, ACTN1, NFKBIA, H2BC5, HIST1H2BC, H2BC9, HIST2H2BE, H2BC12 | More | | Terconazole | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Terconazole | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | | Terconazole | hsa05206 | MicroRNAs in cancer | 4.00E-04 | 13 | P30304, P09493, P15311, P21860, P01106, P42338, P61978, P46531, Q13547, P63279, P22105, P20827, P19174 | CDC25A, TPM1, VIL2, ERBB3, MYC, PIK3CB, HNRPK, NOTCH1, HDAC1, UBE2I, TNXB, EFNA1, PLCG1 | More | | Terconazole | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Terconazole | hsa05214 | Glioma | 1.34E-02 | 4 | P0DP23, P42338, P19174, O75293 | CALM1, PIK3CB, PLCG1, GADD45B | More | | Terconazole | hsa05218 | Melanoma | 2.31E-02 | 3 | Q9NRA1, P42338, O75293 | PDGFC, PIK3CB, GADD45B | More | | Terconazole | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Terconazole | hsa05220 | Chronic myeloid leukemia | 2.17E-02 | 5 | Q13547, P01106, P25963, P42338, O75293 | HDAC1, MYC, NFKBIA, PIK3CB, GADD45B | More | | Terconazole | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Terconazole | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Terconazole | hsa05231 | Choline metabolism in cancer | 2.92E-03 | 5 | P42338, Q9NRA1, Q9Y259, P19174, P23743 | PIK3CB, PDGFC, CHKB, PLCG1, DGKA | More | | Terconazole | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.49E-04 | 13 | P25963, P42338, O95267, P19174, P07766, P20963, P09693, P06239, P42224, O60603, Q04759, Q16539, P01730 | NFKBIA, PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, STAT1, TLR2, PRKCQ, MAPK14, CD4 | More | | Terconazole | hsa05310 | Asthma | 1.35E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Terconazole | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Terconazole | hsa05321 | Inflammatory bowel disease | 1.45E-02 | 2 | P84022, Q9HBE5 | SMAD3, IL21R | More | | Terconazole | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Terconazole | hsa05330 | Allograft rejection | 1.76E-03 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | | Terconazole | hsa05332 | Graft-versus-host disease | 3.75E-03 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Terconazole | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Terconazole | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | | Terconazole | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Terconazole | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Terconazole | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | | |